Everolimus Tablet Franchise in Ahmedabad

Everolimus 0.75 mg Tablet Supplier in Mumbai

Immunosuppressant Tablet Distributor in Delhi

Everolimus Tablet Manufacturer in Bangalore

Transplant & Oncology Medicine Stockist in Hyderabad
Everolimus Tablet Exporter in Chandigarh

Home/Products /everolimus-0-75mg-tablet

Everloop 0.75 Tablet

Composition : Everolimus (0.75mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Everloop 0.75 Tablet contains Everolimus 0.75 mg, a potent mTOR (mammalian target of rapamycin) inhibitor widely used in organ transplant medicine and selected oncology treatments. It helps in suppressing immune responses that may otherwise lead to graft rejection or uncontrolled cell proliferation.

Everolimus works by inhibiting T-cell activation and proliferation, thereby providing effective immunosuppression while maintaining controlled therapeutic action. This mechanism makes it an important component in renal and other solid organ transplant regimens, as well as in targeted cancer therapies.

Clinically, Everolimus 0.75 mg is preferred when precise dose titration is required, allowing physicians to balance efficacy and safety based on patient-specific needs. Its consistent bioavailability supports long-term treatment protocols under strict medical supervision.

Everloop 0.75 Tablet is suitable for hospital supply chains, transplant centers, oncology clinics, and specialty pharmacies, where reliability, dosage accuracy, and compliance with immunosuppressive standards are critical.

Read More

About the Product

Everloop 0.75 Tablet contains Everolimus 0.75 mg, a potent mTOR (mammalian target of rapamycin) inhibitor widely used in organ transplant medicine and selected oncology treatments. It helps in suppressing immune responses that may otherwise lead to graft rejection or uncontrolled cell proliferation.

Everolimus works by inhibiting T-cell activation and proliferation, thereby providing effective immunosuppression while maintaining controlled therapeutic action. This mechanism makes it an important component in renal and other solid organ transplant regimens, as well as in targeted cancer therapies.

Clinically, Everolimus 0.75 mg is preferred when precise dose titration is required, allowing physicians to balance efficacy and safety based on patient-specific needs. Its consistent bioavailability supports long-term treatment protocols under strict medical supervision.

Everloop 0.75 Tablet is suitable for hospital supply chains, transplant centers, oncology clinics, and specialty pharmacies, where reliability, dosage accuracy, and compliance with immunosuppressive standards are critical.

Common side effects may include mouth ulcers, nausea, diarrhea, fatigue, rash, infections, and elevated blood lipid levels. Less commonly, patients may experience delayed wound healing, anemia, thrombocytopenia, lung toxicity, or severe infections.

Everloop 0.75 Tablet is indicated for the prevention of organ transplant rejection when used in combination with other immunosuppressive therapies. It is also used for the treatment of certain malignancies and benign tumors, including renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex–associated conditions, as directed by a specialist.

Everloop 0.75 Tablet should be taken strictly under specialist supervision. Regular monitoring of blood counts, kidney function, lipid profile, and drug levels is essential. Inform your doctor about any ongoing infections, liver impairment, or concurrent medications. Avoid live vaccines during therapy and seek immediate medical care if symptoms such as persistent cough, fever, or breathing difficulty occur.

Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch